Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Mar;97(13):e0197.
doi: 10.1097/MD.0000000000010197.

The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis

Guoqiang Tan  1 , Chang Chu, Xiujuan Gui, Jinyuan Li, Qiufang Chen
Affiliations
Meta-Analysis

The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis

Guoqiang Tan et al. Medicine (Baltimore). 2018 Mar.

Abstract

Background: Circulating cell-free DNA (cfDNA) isolated from plasma or serum by noninvasive procedures can serve as a "liquid biopsy" and has potential as a biomarker for the tumor burden and survival prediction of breast cancer (BC). However, its prognostic value in patients with BC is currently under debate. The aim of this meta-analysis was to investigate the relationship between cfDNA and survival outcome.

Methods: We systematically searched PubMed, Embase, and Science Citation Index electronic databases for studies about the prognostic utility of cfDNA in patients with BC. The clinical characteristics, relapse/disease-free survival (RFS/DFS), and overall survival (OS) data were extracted from the eligible studies. The hazard ratios (HR) and 95% confidence intervals (CI) were calculated and pooled with a fixed-effects model using the Stata12.0 software. Subgroup and sensitivity analyses were also performed.

Results: This meta-analysis included a total of 10 eligible studies and 1127 patients with BC. The pooled HR with 95% CI showed strong associations between cfDNA and OS (HR = 2.41, 95% CI, 1.83-3.16) along with DFS/RFS (HR = 2.73, 95% CI, 2.04-3.67) in patients with BC. Although publication bias was found in the studies regarding RFS/DFS, further trim and fill analysis revealed that the adjusted HR would be 2.53 (95% CI, 1.83-3.51), which is close to the original HR. Subgroup analyses confirmed the role of cfDNA as a strong prognostic marker in patients with BC, regardless of cfDNA analysis, sampling time, sample source, detection method, tumor stage, sample size, or area.

Conclusions: Our meta-analysis indicates that cfDNA is a strong predictive and prognostic marker in patients with BC.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow chart of studies selection.
Figure 2
Figure 2
Forest plot of hazard ratios for correlations between cfDNA analysis and OS.
Figure 3
Figure 3
Forest plot of hazard ratios for correlations between cfDNA analysis and RFS/DFS.
Figure 4
Figure 4
Funnel plots of publication bias for OS (A) and RFS/DFS (B) in present meta-analysis.
Figure 5
Figure 5
Funnel plots of trim and fill analysis for RFS/DFS in present meta-analysis.
Figure 6
Figure 6
Cumulative meta-analyses of OS by publication year.
Figure 7
Figure 7
Cumulative meta-analyses of RFS/DFS by publication year.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. - PubMed
    1. Siegel R, Ma JM, Zou ZH, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29. - PubMed
    1. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010;411:1869–74. - PubMed
    1. Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 2013;133:1–3. - PubMed
    1. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 1948;142:241–3. - PubMed

Publication types